Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 14, 2016. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Transaction Type | Instrument | Price (GBP) | Total Volume |
|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (25p each) | 16.9845 | 234 shares |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by executives and their associates resulting from the re-investment of dividends paid on October 13, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific share transactions executed on the London Stock Exchange (XLON).
Investor Verification Points
- Transaction Nature: Verify that all reported share acquisitions were executed via dividend re-investment plans within Individual Savings Accounts (ISAs).
- Participants: Confirm the identities of the PDMRs and PCAs involved: Sir Andrew Witty (CEO), Mr D S Redfern (Chief Strategy Officer), Mrs V A Whyte (Company Secretary), Lady C Witty (PCA), and Mr J P Witty (PCA).
- Pricing Consistency: Note that all transactions occurred at a uniform price of £16.9845 per share on October 14, 2016.
- Volume Breakdown: Individual share counts were 98 (Witty), 19 (Redfern), 17 (Whyte), 45 (Lady Witty), and 55 (Mr J P Witty).